Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves private label ibuprofen PM

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Perrigo's OTC ibuprofen and diphenhydramine citrate tablets, the Allegan, Mich.-based private-labeler says Dec. 29. Perrigo will ship the product in the first quarter of 2009. Estimated sales of the comparable Wyeth Consumer Healthcare product, Advil PM tablets, were $70 million in the 12 months ending Sept. 28 (1"The Tan Sheet" Nov. 3, 2008, In Brief)

You may also be interested in...



Perrigo readies ibuprofen/PM launch

The company says Oct. 29 it expects final clearance to launch a private-label version of Wyeth Consumer Healthcare's Advil PM tablets after Wyeth's exclusivity ends, Dec. 21, 2008. FDA granted tentative approval for Perrigo's abbreviated new drug application for the non-steroidal anti-inflammatory drug (ibuprofen 200 mg and diphenhydramine citrate 38 mg) indicated as a pain reliever and sleep-aid. According to Allegan, Mich.-based Perrigo, Advil PM U.S. sales totaled $70 million in the 12 months ending Sept. 28. Perrigo includes sales of an ibuprofen/diphenhydramine citrate product in the $275 million it expects to generate from more than 25 products launched between February 2007 and June 2009 (1"The Tan Sheet" Aug. 25, 2008, p. 11)

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel